Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients

Temiz, Gökhan; Kaşifoğlu, Nilgün; Kiris, Alpay; Özkurt, Sultan; Şahin, Garip; Yalçın, Ahmet; Us, Tercan

doi:10.3109/0886022x.2010.486498

Cited by 12 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning H1N1 vaccination, one of the leading debates is whether a single dose of vaccine should be administered or whether a perpetuation vaccine is necessary [7]. In our study, we found that in the whole CKD group, the rate of seroconversion after a single dose of the vaccine was 84 and 78% in the patient and control groups, respectively.…”

Section: Discussionsupporting

confidence: 60%

“…Especially in patients under the age of 50 years, due to a stronger immune system, seroconversion rates were found to be higher [10,11]. In a study conducted in Turkey, the vaccine response in HD patients was found to be higher than in the control group, and it was also reported that a single dose of the vaccine was sufficient for the formation of an antibody response [7]. Song et al [12] also reported that influenza vaccination in HD patients constituted an effective humoral immune response and that there was no significant difference between antibody responses in HD patients who had either a single-dose or double-dose vaccine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Effectiveness of a 2009 H1N1 Vaccine in Chronic Kidney Disease Children

Akacı¹,

Albayrak²,

Altaş³

2014

Nephron Clin Pract

View full text Add to dashboard Cite

Background/Aims: Influenza vaccination is the most effective method for preventing influenza infection and its complications. The risk groups are children with chronic kidney diseases (CKDs) such as children on peritoneal dialysis (PD) and hemodialysis (HD), predialysis CKD (pCKD) and renal transplant (RTx) patients and immunosuppressed children. The aim of the present study was to assess the safety and immunogenicity of a single administration of a monovalent inactivated pandemic (H1N1) 2009 vaccine in children with CKD. Methods: Patients were given a single intramuscular injection of 0.5 ml of monovalent inactivated vaccine. Results: Totally, there were 25 pediatric patients with a diagnosis of CKD (16 PD, 2 HD, 3 pCKD and 4 RTx). Seroconversion was observed in 15 of the 16 patients with PD. Seroconversion occurred in all patients undergoing pCKD and HD. However, 3 of the RTx patients were seronegative. Conclusion: This study demonstrated a high level of immunogenicity and safety of an (H1N1) 2009 influenza vaccine in children with CKD.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Safety and Effectiveness of a 2009 H1N1 Vaccine in Chronic Kidney Disease Children

Akacı¹,

Albayrak²,

Altaş³

2014

Nephron Clin Pract

View full text Add to dashboard Cite

show abstract

“…Since European inXuenza season lasts about 4.5 months [33], a durable antibody response is desirable. In contrast to HI-based studies, two investigations conducted with enzyme immunoassays have described a profound serological response to pandemic H1N1 vaccination in those patients [27,29]. However, a recent analysis revealed that an enzyme-linked immunosorbent assay that was indicated to be speciWc to the detection of IgG antibodies against the pandemic H1N1 strain is of only limited value for the determination of post-vaccination status [31].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have analyzed the serological response to vaccination against pandemic H1N1 in renal transplant recipients and hemodialysis patients [9,[26][27][28][29][30]. Comparable to the present analysis, most of these studies used the hemagglutination inhibition (HI) assay to measure relevant HI titers.…”

Section: Discussionmentioning

confidence: 99%

“…Comparable to the present analysis, most of these studies used the hemagglutination inhibition (HI) assay to measure relevant HI titers. Two reports are based on data obtained by enzyme immunoassay technique [27,29], and in one report, neutralizing antibodies against pandemic H1N1 were determined [28]. To our knowledge, the present investigation is the only study on hemodialysis patients and renal transplant recipients, which investigates serological response to pandemic H1N1 vaccination and seasonal inXuenza vaccination in parallel.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Ott

Sauerbrei

Lange

et al. 2012

Med Microbiol Immunol

View full text Add to dashboard Cite

In the present study, antibody response to seasonal influenza vaccination and to the adjuvanted one-shot influenza A H1N1 vaccine (Pandemrix(®)) was investigated in 57 hemodialysis (HD) patients and 48 renal transplant (RT) recipients. Specific antibodies were measured by hemagglutination inhibition (HI) test using a pandemic H1N1 strain and a seasonal H3N2 virus. HI titers of ≥1:40 were considered as protective. Hemodialysis patients showed seroprotection against pandemic H1N1 in 35.1%, against seasonal influenza in 36.8% and against both in 14.0%. In comparison, renal transplant recipients developed protective antibody titers against the pandemic H1N1 virus in 47.9%, against the seasonal H3N2 strain in 31.3% and against both in 18.8%. HD patients and renal transplant recipients younger than 60 years developed protective antibody response to the pandemic influenza H1N1 vaccine in 50.0% of the HD patients and 55.2% of the RT recipients and against seasonal influenza in 45.0/20.7% (HD/RT) of the cases. Patients aged ≥60 years showed seroprotection against pandemic influenza in 27.0/36.8% (HD/RT) and against seasonal influenza in 32.4/47.4% (HD/RT). Side effects were reported in only four patients. In hemodialysis patients and renal transplant recipients, vaccination against pandemic H1N1 and seasonal influenza is well tolerated. However, more than a half of these patients did not develop seroprotective antibody levels. Thus, new vaccines and altered vaccination regimes are likely necessary to achieve relevant antibody levels in these patient groups.

show abstract

Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients

Son

Lee

et al. 2012

Clin Exp Nephrol

View full text Add to dashboard Cite

A single 3.75-μg dose of MF59-adjuvanted vaccine was suboptimal to elicit protective antibody response in dialysis patients. Antibody responses against vaccine were compromised especially in elderly PD patients. Trials of different vaccination protocols such as a two-dose schedule or a higher hemagglutinin antigen dose of MF59-adjuvanted vaccine are necessary for improving antibody response in dialysis patients.

show abstract

Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients

Abstract: H1N1 vaccine can be performed safely and cost effectively with a single dose to the risk groups especially to the hemodialysis patients. Evaluation of H1N1 IgG antibody with enzyme-linked immunosorbent assay (ELISA) may be a safe, easy, and cost-effective assay.

Cited by 12 publications

References 14 publications

Safety and Effectiveness of a 2009 H1N1 Vaccine in Chronic Kidney Disease Children

Safety and Effectiveness of a 2009 H1N1 Vaccine in Chronic Kidney Disease Children

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients

Contact Info

Product

Resources

About